Semaglutide
Semaglutide
The most clinically validated peptide for weight loss and metabolic health.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | GLP-1 Receptor Agonist |
| Half-Life | ~7 days |
| Administration | Subcutaneous injection (weekly), Oral tablet (daily) |
| Typical Dosage | 0.25 mg/week (starting), titrating to 1–2.4 mg/week |
| Cycle Length | Ongoing — typically 12–24+ weeks |
| Evidence Level | Strong Human Clinical |
| Legal Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) — requires prescription |
| Approximate Cost | $200–$1,200/month (brand); $150–$400/month (compounded via telehealth) |
How Semaglutide Works
Activates GLP-1 receptors in the hypothalamus and GI tract, reducing appetite, slowing gastric emptying, and improving insulin secretion.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the endogenous hormone GLP-1. It acts on GLP-1 receptors in the hypothalamus to reduce appetite and food cravings, in the GI tract to slow gastric emptying (increasing satiety), and in the pancreas to stimulate glucose-dependent insulin secretion. The weekly injectable formulation achieves sustained receptor activation that produces clinically meaningful reductions in caloric intake and body weight.
Evidence Base
Preclinical Evidence
Extensive preclinical data supporting weight reduction, improved insulin sensitivity, and cardiovascular risk reduction.
Human Evidence
Among the most extensively studied peptides in clinical medicine. The SUSTAIN and STEP trial programs demonstrate 10–15% average body weight reduction with Semaglutide 2.4 mg weekly. Cardiovascular outcome trials (LEADER, SUSTAIN-6) show significant reductions in major adverse cardiovascular events.
Anecdotal Evidence
Semaglutide has become mainstream, with widespread use in both medical and non-medical settings. Users consistently report significant appetite suppression, particularly for ultra-processed foods. The 'food noise' reduction effect is frequently cited as the most transformative aspect of the treatment.
Key PubMed References:
Safety Profile
Side Effects
Nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation. Rare but serious: pancreatitis, gallbladder disease, thyroid C-cell tumors (in rodents — human risk unclear). Muscle mass loss with rapid weight reduction is a concern.
Contraindications
Personal or family history of medullary thyroid carcinoma or MEN2. Active pancreatitis. Pregnancy.
PeptidePilot Assessment
Semaglutide is PeptidePilot's top recommendation for users whose primary goal is significant, sustained weight loss and metabolic health improvement. In our algorithm, it scores highest for users who report carrying excess body fat, appetite control challenges, and metabolic concerns. Because it requires a prescription, we route Semaglutide-matched users to our telehealth partners. We always recommend Semaglutide alongside resistance training to preserve lean muscle mass.
📊 28% of PeptidePilot users with fat loss as their primary goal receive Semaglutide/Tirzepatide as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.